1Ring J, Gutermuth J. 100 years of hyposensitization: historyof allergen-sepcific immunotherapy (ASIT) [J]. Allergy, 2011, 66: 713-724.
2Noon L. Prophylactic inoculation against hay fever[J]. Lan- cet, 1960, 18: 287-291.
3Freeman J. Further observations on the treatment of hay fe- ver by hypodermic inoculations of pollen vaccine[J]. Lancet, 1960, 18: 427-434.
4Bousquet J, Lockey R, Mailing H J, Allergen immunothera- py: Therapeutic vaccines for allergic diseases. A WHO posi- tion paper[J]. Allergy, 1998, 102( 4 pt 1): 558-562.
5Pfaar O, Barth C, Jaschke C, et al. Sublingual allergen-spe- cific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/II a study[J]. Int Arch Allergy Immunol, 2011, 154: 336-344.
6van Rensen EL, Evertse CE, van Schadewijk WA, etal. Eo- sinophils in bronchial mucosa of asthmatics after allergen challenge., effect of anti-IgE treatment[J]. Allergy, 2009, 64 : 72-80.
7Gronlund H, Gafvelin G. Recombinant Betvl vaccine for treatment of allergy to birch pollen[J]. Hum Vaccine, 2010, 6: 970-977.
8Chua KY, Kuo IC, Huang CH. DNA vaccines for the pre- vention and treatment of allergy[J]. Curr Opin Allergy Clin Immunol, 2009, 9: 50-54.
9Worm M, Lee HH, Kleine-Tebhe J, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy[J]. J Allergy Clin Immunol, 2011, 127 : 89-97.
10Senti G, von Moos S, Tay F, et al. Epicutaneous allergen- specific immunotherapy ameliorates grass pollen-induced rhi noconjunetivitis: A double-blind, placebo-controlled dose es- calation study[J]. J Allergy Clin Immunol, 2012, 129: 128- 135.
4Bousquet J, Lockey R, Mailing HJ. Allergen immunotherapy : thera- peutic vaccines for allergic diseases. A WHO position paper[ J]. J Allergy Clin Immunol, 1998,102 (4Ptl) :558 -562.
5Bousquet J, Van Cauwenberge P, Khaitaev N, et al. Allergic rhi- nitis and its impact on asthma [ J]. J Allergy Clin Immunol, 2001,108 (Suppl) : 147 - 150.
6Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical ailergen-specificimmunotherapy [ J ]. Allergy, 2006, 61Suppl182:1 -2.
7Steinman L. A brief history of T(H) 17, the first major revision in theT ( H ) 1/T (H) 2 hypothesis of T-cel-mediated tissue damage [J]. Nat Med,2007,13(2) :139 - 145.
8Ciprandi G, Fenoglio D, De Amici M, et al. Serum IL-17 levels in patients with allergic rhinitis [ J ]. Allergy Clin Immunol, 2008, 122(3) :650 -651.
9Canonlca GW, Bousquet J, Casale T, et al. Sub-lingualimmuno- therapy:World allergy organization position paper 2009 [ J ]. Al- lergy,2009,64Supp191 : 1 - 59.
10Incorvaia C, Mauro M, Ridolo E, et al. Patient' s compliance with allergen immunotherapy [ J ]. Patient Prefer Adherence,2008,2 : 247 -251.
